



## **COLLABORATIVE WORKING EXECUTIVE SUMMARY**

**Project Title:** Primary Care Breast Pain Clinic

### **Project Description**

Roche Products Ltd. and HEALTH IMPROVEMENT TRANSFORMATION STRATEGIES LIMITED - HITS propose to work together under a Collaborative Working Agreement to support the rollout of the Breast Pain Clinic model to additional geographical locations.

### **Organisations Involved**

Roche and HITS have contributed resources to this project.

### **Project Rationale**

Roche and HITS are dedicated to improving the diagnosis and care of breast patients, through the Community Breast Pain Clinic successfully implemented by clinicians in Nottinghamshire'. This is an example of successful integration between primary, secondary and community care, leading to transformation of the breast cancer service.

The evidence based clinic and family history risk assessment has resulted in the more efficient triage of symptomatic patients with breast pain from a primary care setting in the Nottinghamshire area.

Roche and HITS are working in partnership under a collaborative working agreement to:

1. Facilitate rapid adoption and implementation of similar clinics into other localities across the NHS.
2. Collect and analyse data generated as a result of the collaboration with a view to sharing outcomes with the NHS and a wider stakeholder group.
3. Progress of the project will be tracked by a designated steering committee, which will consist of members both from HITS and Roche.

### **Project period**

Project Start Date: July 2021

Project End Date: July 2022

### **Project Outcome**

#### **Benefit for patients**

Delivery of improved care for breast patients with appropriate triage to either i) familial cancer service, or ii) the breast cancer service resulting in early assessment, diagnosis and treatment for better patient outcomes. Enhanced confidence and education for patients with breast pain alone.

**Benefit to the NHS**

Decrease in inappropriate referrals into secondary care and decreased pressure on the 2 week wait pathway. Identification and recording of patients with familial history of breast cancer. Enhanced integration of primary and secondary care to collectively provide better patient outcomes for patients in their locality.

**Benefit to Roche**

To further understand breast cancer service design in order to inform future product and service development. Increase appropriate early use of medicines, which may include Roche medicines.

**This document has been produced by Roche Products Ltd and HITS – HEALTH IMPROVEMENT TRANSFORMATION STRATEGIES LIMITED**